Polivy
Polivy ingredients
| Active ingredient | Strength |
|---|---|
| Polatuzumab Vedotin | 140 mg/7.52mL, 30 mg/1.88mL |
What Polivy is used for
The FDA lists the approved uses on the official label (below). In the EU, polatuzumab vedotin is approved as Polivy for:
Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Polivy
- Generic name
- Polatuzumab vedotin
- Made by
- Genentech, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761121
- On the US market since
- 2019
Official information
- Polivy prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Polatuzumab vedotin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Polivy?
Polivy (Polatuzumab vedotin) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Polivy?
Polivy contains Polatuzumab Vedotin (140 mg/7.52mL, 30 mg/1.88mL).
Is Polivy approved in Europe?
The same active substance is approved in the EU as Polivy.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA